Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_2
1
33%
Ph not_applicable
1
33%
Ph phase_4
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Completed1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

completed133%
not_yet_recruiting133%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_2

Trial of Oral Community SVMP INhibitors for Snakebite

NCT07500233
completedphase_4

Oracea Soolantra Association in Participants With Severe Rosacea

NCT03075891
terminatednot_applicable

Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy

NCT01213888

Clinical Trials (3)

Showing 3 of 3 trials
NCT07500233Phase 2

Trial of Oral Community SVMP INhibitors for Snakebite

Not Yet Recruiting
NCT03075891Phase 4

Oracea Soolantra Association in Participants With Severe Rosacea

Completed
NCT01213888Not Applicable

Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3